دورية أكاديمية
Heterologous and homologous COVID-19 mRNA vaccination schemes for induction of basic immunity show similar immunogenicity regarding long-term spike-specific cellular immunity in healthcare workers.
| العنوان: | Heterologous and homologous COVID-19 mRNA vaccination schemes for induction of basic immunity show similar immunogenicity regarding long-term spike-specific cellular immunity in healthcare workers. |
|---|---|
| المؤلفون: | Wagenhäuser I; Infection Control and Antimicrobial Stewardship Unit, University Hospital Würzburg, Würzburg, 97080, Germany; Department of Internal Medicine I, University Hospital Würzburg, Würzburg, 97080, Germany., Almanzar G; Pediatric Rheumatology/Special Immunology / Department of Pediatrics, University Hospital Würzburg, Würzburg, 97080, Germany., Förg FB; Pediatric Rheumatology/Special Immunology / Department of Pediatrics, University Hospital Würzburg, Würzburg, 97080, Germany., Stein A; Pediatric Rheumatology/Special Immunology / Department of Pediatrics, University Hospital Würzburg, Würzburg, 97080, Germany., Eiter I; Infection Control and Antimicrobial Stewardship Unit, University Hospital Würzburg, Würzburg, 97080, Germany., Reusch J; Infection Control and Antimicrobial Stewardship Unit, University Hospital Würzburg, Würzburg, 97080, Germany; Department of Internal Medicine I, University Hospital Würzburg, Würzburg, 97080, Germany., Mees J; Infection Control and Antimicrobial Stewardship Unit, University Hospital Würzburg, Würzburg, 97080, Germany., Herzog A; Department of Internal Medicine I, University Hospital Würzburg, Würzburg, 97080, Germany., Vogel U; Infection Control and Antimicrobial Stewardship Unit, University Hospital Würzburg, Würzburg, 97080, Germany; Institute for Hygiene and Microbiology, Julius-Maximilians-Universität Würzburg, Würzburg, 97080, Germany., Frey A; Department of Internal Medicine I, University Hospital Würzburg, Würzburg, 97080, Germany., Lâm TT; Institute for Hygiene and Microbiology, Julius-Maximilians-Universität Würzburg, Würzburg, 97080, Germany., Schubert-Unkmeir A; Institute for Hygiene and Microbiology, Julius-Maximilians-Universität Würzburg, Würzburg, 97080, Germany., Dölken L; Institute for Virology and Immunobiology, Julius-Maximilians-Universität Würzburg, Würzburg, 97080, Germany., Kurzai O; Institute for Hygiene and Microbiology, Julius-Maximilians-Universität Würzburg, Würzburg, 97080, Germany; Leibniz Institute for Natural Product Research and Infection Biology - Hans-Knoell-Institute, Jena, 07745, Germany., Frantz S; Department of Internal Medicine I, University Hospital Würzburg, Würzburg, 97080, Germany., Gabel A; Infection Control and Antimicrobial Stewardship Unit, University Hospital Würzburg, Würzburg, 97080, Germany., Petri N; Department of Internal Medicine I, University Hospital Würzburg, Würzburg, 97080, Germany., Prelog M; Pediatric Rheumatology/Special Immunology / Department of Pediatrics, University Hospital Würzburg, Würzburg, 97080, Germany. Electronic address: martina.prelog@uni-wuerzburg.de., Krone M; Infection Control and Antimicrobial Stewardship Unit, University Hospital Würzburg, Würzburg, 97080, Germany; Institute for Hygiene and Microbiology, Julius-Maximilians-Universität Würzburg, Würzburg, 97080, Germany. |
| المصدر: | Vaccine [Vaccine] 2024 Aug 30; Vol. 42 (21), pp. 126132. Date of Electronic Publication: 2024 Jul 20. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Elsevier Science Country of Publication: Netherlands NLM ID: 8406899 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-2518 (Electronic) Linking ISSN: 0264410X NLM ISO Abbreviation: Vaccine Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Amsterdam, The Netherlands : Elsevier Science Original Publication: [Guildford, Surrey, UK] : Butterworths, [c1983- |
| مواضيع طبية MeSH: | Spike Glycoprotein, Coronavirus*/immunology , Health Personnel* , COVID-19*/prevention & control , COVID-19*/immunology , BNT162 Vaccine*/immunology , SARS-CoV-2*/immunology , Antibodies, Viral*/blood , Antibodies, Viral*/immunology , COVID-19 Vaccines*/immunology , COVID-19 Vaccines*/administration & dosage , Immunity, Cellular*/immunology, Humans ; Female ; Male ; Middle Aged ; Adult ; 2019-nCoV Vaccine mRNA-1273/immunology ; Vaccination/methods ; Immunoglobulin G/blood ; Immunoglobulin G/immunology ; Immunogenicity, Vaccine ; T-Lymphocytes/immunology ; B-Lymphocytes/immunology |
| مستخلص: | Healthcare workers (HCWs) are recommended to receive at least three spike-antigen exposures to generate basic immunity and to mediate herd protection of vulnerable patients. So far, less attention has been put on the cellular immune response induced by homologous (three BTN162b2mRNA doses) or heterologous (mRNA-1273 as third dose building on two BTN162bmRNA doses) and the immunological impact of breakthrough infections (BTIs). Therefore, in 356 vaccinated HCWs with or without BTIs the Anti-SARS-CoV-2-Spike-IgG concentrations and avidities and B- and T-cell-reactivity against SARS-CoV-2-Spike-S1- and Nucleocapsid-antigens were assessed with Interferon-gamma-ELISpot and by flow-cytometry. HCWs who had hybrid immunity due to BTIs exhibited strong T-cell-reactivity against the Spike-S1-antigen. A lasso regression model revealed a significant reduction in T-cell immune responses among smokers (p < 0.0001), with less significant impact observed for age, sex, heterologous vaccination, body-mass-index, Anti-Nucleocapsid T-cell reactivity, days since last COVID-19-immunization, and Anti-SARS-CoV-2-Spike-IgG. Although subgroup analysis revealed higher Anti-SARS-CoV-2-Spike-IgG after heterologous vaccination, similar cellular reactivity and percentages of Spike-reactive T- and B-cells were found between homologous and heterologous vaccination. Anti-SARS-CoV-2-Spike-IgG concentrations and avidity significantly correlated with activated T-cells. CD4 + and CD8 + responses correlated with each other. A strong long-term cellular immune response should be considered as baseline for recommendations of booster doses in HCWs with prioritization of smokers. HCWs presented significant T-cellular reactivity towards Spike-S1-antigen with particularly strong responses in hybrid immunized HCWs who had BTIs. HCWs without BTI presented similar percentages of Spike-specific B- and T-cells between homologous or heterologous vaccination indicating similar immunogenicity for both mRNA vaccines, BNT162b2mRNA and mRNA-1273. Competing Interests: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Martina Prelog received honoraria for presentations at scientific meetings from Abbvie, BioNTech, Chugai-Roche, Doctorflix, GSK, Esanum, Janssen, Novartis, Moderna, MSD, Pfizer, Sanofi and SOBI, received honoraria for advisory boards from Abbvie, BioNTech, GSK, Janssen, Moderna, Novartis, and Pfizer , received travel scholarships from Chugai-Roche, GSK, Novartis and Pfizer, received financial support for conduction of investigator-initiated research from Baxter, Chugai-Roche, Galapagos, GSK, Moderna, Novartis, MSD, Pfizer and SOBI; Martina Prelog declares to have no conflict of interest regarding the manuscript. Manuel Krone receives honoraria from GSK and Pfizer outside the submitted work. All other authors declare no potential conflicts of interest. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper]. (Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.) |
| فهرسة مساهمة: | Keywords: Anti-SARS-CoV-2-Spike IgG; COVID-19 vaccination; Healthcare workers; T-SPOT.COVID; T-cellular immunity |
| المشرفين على المادة: | 0 (Spike Glycoprotein, Coronavirus) 0 (BNT162 Vaccine) 0 (Antibodies, Viral) 0 (COVID-19 Vaccines) 0 (spike protein, SARS-CoV-2) EPK39PL4R4 (2019-nCoV Vaccine mRNA-1273) 0 (Immunoglobulin G) |
| تواريخ الأحداث: | Date Created: 20240721 Date Completed: 20240821 Latest Revision: 20240821 |
| رمز التحديث: | 20240822 |
| DOI: | 10.1016/j.vaccine.2024.07.033 |
| PMID: | 39034219 |
| قاعدة البيانات: | MEDLINE |
Full Text via ClinicalKey 
Full Text Finder | تدمد: | 1873-2518 |
|---|---|
| DOI: | 10.1016/j.vaccine.2024.07.033 |